First human test for potential muscle disease drug

NCT ID NCT07317063

Summary

This early-stage study tested the safety and how the body processes a single dose of an experimental drug called GRT6019 in 18 healthy male volunteers. Researchers specifically checked if taking the drug with food versus on an empty stomach changed how it was absorbed. The goal was to gather basic safety data and understand how the drug behaves in the body before testing it in people with Duchenne muscular dystrophy.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY (DMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Biotrial, Inc

    Newark, New Jersey, 07103, United States

Conditions

Explore the condition pages connected to this study.